Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

THE TRUTH ABOUT: 8 - Caught on Camera

Trump hints at tariff reprieve for pharma companies that bring operations back to US

He suggests drugmakers would get ‘a lot of time’ to repatriate manufacturing before facing levies

The Guardian - UK

3 Industry Behemoths Are Rewarding Investors With Dividend Bumps

See these three stocks that are among the most important in their industries, which have announced sizable increases in their dividends.

MarketBeat

Swiss drugmaker Roche to invest $50bn in US in effort to dodge Trump tariffs

Company says it will create 12,000 jobs in manufacturing and R&D over next five years

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Netflix stock has been nearly unscathed by Trump tariffs. Some think it could be Silicon Valley’s version of Johnson & Johnson

As recession fears mount on Wall Street, management is still reportedly setting ambitious long-term goals.

Fortune

Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?

Johnson & Johnson had more good than bad; investors should look at the entire report in context before deciding if JNJ stock is a good fit for their portfolios

MarketBeat

Johnson & Johnson expects $400 million in tariff-related costs, mostly related to China

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year

The Independent UK

‘Half the place would be blown to bits’: the Irish villages under threat from Trump’s tariffs

Cork’s pharmaceutical industry, vital to the local economy, is at risk as US trade policies threaten small towns reliant on the sector

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Did pharma sector dodge Trump’s tariffs? The EU's not so sure

The fear of a trade war over pharmaceuticals between the EU and the US has been avoided for now, but the European Commission remains on guard, considering further tariff deployments likely.

Euronews

Stock Market Today: Stocks Are Mixed Before Liberation Day

Markets are getting into the freewheeling rhythm of a second Trump administration.

Kiplinger

3 Dividend Stocks to Buy for a Safe Haven in This Volatile Market

The consistency in their dividend payments makes them dependable stocks in a volatile market.

Barchart

Resilient Investing: 3 Stocks Built to Weather Market Volatility

Resilient companies with strong financials and diverse revenue in healthcare, technology, and essential services can offer stability in volatile markets.

MarketBeat

Is Johnson & Johnson Stock Underperforming the Dow?

Despite Johnson & Johnson’s underperformance relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

3 Dividend-Paying Stocks Bucking the Market’s Trend

Despite a relentless market-wide selloff on Friday, Coca-Cola, Johnson & Johnson, and McDonald’s showed notable strength, defying the broader downtrend.

MarketBeat

3 "Forever Stocks" You Can Buy and Hold for Decades

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in the economic and geopolitical spheres. In this volatile environment, investors may find value in fundamentally stable stocks like Microsoft (MSFT), Alphabet (GOOGL), and Johnson & Johnson (JNJ). Continue to read….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Thousands to sue Johnson & Johnson in UK over alleged talc link to cancer

Group action with 3,500 claimants alleges company knew its talcum powder products contained dangerous asbestos

Barchart

Johnson & Johnson Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Johnson & Johnson's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

2 Dividend Kings You Should Snap Up Immediately

Recent earnings from these dividend-paying companies reflects their stability.

Fortune

How tech leaders are rethinking their cloud strategies in the face of fast-rising costs

As spending on cloud computing rises sharply amid the generative AI boom, executives are on the hunt for cost savings.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

3 Stocks Upgraded by Bank of America – Here's Why They're Bullish

Bank of America analysts have recently shifted their views on these three stocks, leaving investors with a few points to consider.

Barchart

Technology Stocks Upended by China’s DeepSeek

The S&P 500 Index ($SPX ) (SPY ) Monday closed down -1.46%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.65%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.97%. March E-mini S&P futures (ESH25 ) are down by -1.38%, and March E-mini Nasdaq...

MarketBeat

Why Traders Are Buying the Dip on Johnson & Johnson Stock

Shares of Johnson & Johnson stock have declined by 11.5% in the quarter, and markets are calling for a bottom and rally here.

MarketBeat

Abbott Laboratories Will Outperform Healthcare Stocks in 2025

Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026.

Fortune

Ketamine-derived nasal spray for depression now FDA-approved as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Barchart

Stocks March Higher as Netflix and Oracle Soar

The S&P 500 Index ($SPX ) (SPY ) today is up +0.49%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.10%. March E-mini S&P futures (ESH25 ) are up +0.52%, and March E-mini Nasdaq futures...

MarketBeat

Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.